Date of publication: February 08, 2021
Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Vaccine AstraZeneca. This assessment follows the HTAC evaluation framework to assess COVID-19 vaccines using the following criteria: (1) responsiveness to magnitude and severity; (2) clinical efficacy and safety; (3) affordability and viability; (4) household financial impact; (5) social impact; and (6) responsiveness to equity.
Guidance for General Public: https://hta.doh.gov.ph/2021/02/16/covid-19-vaccine-astrazeneca-under-emergency-use-authorization/
Guidance for General Public (Filipino): https://hta.doh.gov.ph/2021/04/14/gabay-sa-publiko-tungkol-sa-covid-19-vaccine-astrazeneca/
Guidance for Health Care Provider: https://hta.doh.gov.ph/2021/02/16/covid-19-vaccine-chadox1-s-recombinant-covid-19-vaccine-astrazeneca-guidance-for-health-care-providers/
Guidance for Health Care Provider (Filipino): https://hta.doh.gov.ph/2021/04/19/gabay-sa-mga-health-care-provider-tungkol-covid-19-vaccine-chadox1-s-recombinant-covid-19-vaccine-astrazeneca/
Evidence summary: bit.ly
HTAC Recommendation Preview: